Pay in 4 interest-free payments of $7.13 Learn more
Ships within 48 hours · Estimated delivery Aug 8 - Aug 13
GLP-1 Receptor Agonist Market Key Takeaways Eli Lilly and Company, Sanofi, Novo-Nordisk A/S, AstraZeneca, Pfizer, Inc., Amgen, Inc., Innovent Biologics, Inc., PegBio Co., Ltd., Sun Pharmaceutical Industries Ltd., Boehringer Ingelheim International GmbH Increasing prevalence of chronic diseases such as diabetes and obesity Increasing R&D activities for developing novel therapeutics Formulation advancements of oral GLP-1 receptor agonists Adverse effects associated with few GLP-1 agonist drugs Product recalls by market players With the increasing prevalence of diabetes and obesity, GLP-1 receptor agonists have become popular due to their effectiveness in glycemic control and weight reduction, offering a dual benefit in managing type 2 diabetes mellitus (T2DM)
The term "oral peptide" in consumer usage encompasses any GLP-1 medication designed for non-injectable administration
You need to know about rare but serious adverse effects and how to recognize them
What Happens During Short-Term Use
American Academy of Allergy Asthma and Immunology
If youre interested in Semaglutide, discuss your eligibility with your healthcare provider
US$ 20.01
US$ 26.65
US$ 29.88
